Hormone Replacement Therapy Market Regional Insights by Top Key Players | Novartis AG, Abbott Laboratories, Mylan N.V., Merck KgaA, Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals

Increasing number of people suffering from hypogonadism and rising adoption of testosterone products in various economies is expected to propel overall growth of the market. According to the data published in the European Association of Urology Journal: 2017, testosterone prescription trends in the U.S. exhibited an increase between 1.8- and 4-fold over the last two decades (1997 - 2017). Moreover, from 2000 to 2011, there was a 4.3-fold increase in testosterone testing when compared to a 3.7-fold increase in prescriptions.

Rising number of generic versions of hormone replacement therapies by various manufacturers will drive growth of the market in terms of volume and value. For instance, Teva Pharmaceutical Industries Ltd. launched the generic Axiron1 (testosterone) topical solution CIII, 30 mg/1.5 mL, in the U.S. on August 18, 2017 to treat adult males who have low or no testosterone due to certain medical conditions. This solution was supplied in a metered dose pump with an underarm applicator.

However, high cost associated with the replacement therapy and complex reimbursement scenario that causes excluding of the therapy from coverage by insurers, as it is a rare disease, hampers growth of the hormone replacement therapy market.

Get PDF Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2079

Extensive research in the field of nephrology developing new drugs and therapies for the treatment of secondary hyperparathyroidism is fueling growth of the hormone replacement therapy market. For instance, Sanofi SA’s Hectorol capsules is undergoing Phase 3 clinical trials to evaluate the safety and efficacy of this medication in reducing the level of secondary hyperparathyroidism in pediatric patients with chronic kidney diseases at stage 3 and 4. The clinical trials of the drug is expected to be completed in December 2017 and then, will be commercially available in the market.

Increasing collaborations amongst key companies to fast-track the development of therapies for hormone replacement is expected to boost growth of the hormone replacement therapy market size. For instance, in March 2018, Shire plc entered into a preclinical research collaboration with NanoMedSyn, a French biotech company, to develop enzyme replacement treatment for a lysosomal storage disorder based on NanoMedSyn’s synthetic derivative technology named AMFA.

Manufacturers in hormone replacement therapy market are focused on expansion of their product portfolio through continuous launching of generic products, especially in the U.S.

For instance, in January, 2018, Teva Pharmaceutical Industries Ltd. launched an authorized generic version of Estrace1 Cream (estradiol vaginal cream, USP, 0.01%), in the U.S. for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. This launch is an important addition to Teva’s generic women’s health portfolio and their growing line of menopause treatments, which is expected to propel growth of the hormone replacement therapy market over the forecast period.

Download PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2079

Furthermore, increasing adoption of hormone replacement therapies in various countries is expected to drive growth of the market. In August 2017, Abbott Laboratories got regulatory approval in Russia and the Netherlands for oral dydrogesterone medicine. Dydrogesterone that was used for over 50 years to treat conditions related to progesterone insufficiency is now approved as a treatment option for preparing the uterus in women who undergo in vitro fertilization (IVF) treatment in these countries.

The global hormone replacement therapy market is expected to expand at a CAGR of 5.2% during the forecast period (2018–2026), owing to increasing hormonal disorders, which require prescriptions of such therapies

Among therapy type, estrogen hormone replacement therapy segment accounts for major market share, as the U.S. Food and Drug Administration (FDA) approved many hormone products for use in menopausal hormone therapy (MHT). Drugs such as Premarin, Menest, and Combipatch are major contributors to the market revenue. According to the reports published by Pfizer, Premarin independently recorded a sale of 1,076 million in 2014.

Major players operating in the global hormone replacement therapy market include Novartis AG, Abbott Laboratories, Mylan N.V., Merck KgaA, Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Amgen, Inc., and Eli Lilly and Company

Purchase this Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/2079

Contact Us:
Name: Mr. Raj Shah
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About us:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.